# Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

> **NCT03336983** · PHASE2 · COMPLETED · sponsor: **Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia** · enrollment: 126 (actual)

## Conditions studied

- Prostate Cancer
- Bone Metastases

## Interventions

- **DRUG:** Zoledronic Acid
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03336983
- **Lead sponsor:** Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-04-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336983, "Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03336983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*